Looking to expand your partner network with leading companies like ionctura? Consider joining Inpart's global network for free.
Opinion 1 Nov 2023
Could this be the start of a new era for PI3K drugs?
There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs, a type of kinase inhibitor, after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that […]
